WO2004012662A3 - Improved treatment of cancer with glutamine - Google Patents

Improved treatment of cancer with glutamine Download PDF

Info

Publication number
WO2004012662A3
WO2004012662A3 PCT/US2003/023987 US0323987W WO2004012662A3 WO 2004012662 A3 WO2004012662 A3 WO 2004012662A3 US 0323987 W US0323987 W US 0323987W WO 2004012662 A3 WO2004012662 A3 WO 2004012662A3
Authority
WO
WIPO (PCT)
Prior art keywords
glutamine
cancer
improved treatment
enhances
involving
Prior art date
Application number
PCT/US2003/023987
Other languages
French (fr)
Other versions
WO2004012662A2 (en
Inventor
V Suzanne Klimberg
Robert G Ii Petit
Edward C Shinal
Original Assignee
Aesgen Inc
V Suzanne Klimberg
Robert G Ii Petit
Edward C Shinal
Univ Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aesgen Inc, V Suzanne Klimberg, Robert G Ii Petit, Edward C Shinal, Univ Arkansas filed Critical Aesgen Inc
Priority to NZ538405A priority Critical patent/NZ538405A/en
Priority to JP2004526274A priority patent/JP4664071B2/en
Priority to ES03767028T priority patent/ES2405287T3/en
Priority to CA2493764A priority patent/CA2493764C/en
Priority to EP03767028.8A priority patent/EP1572093B1/en
Priority to MXPA05001267A priority patent/MXPA05001267A/en
Priority to AU2003257963A priority patent/AU2003257963B2/en
Publication of WO2004012662A2 publication Critical patent/WO2004012662A2/en
Priority to IL166475A priority patent/IL166475A/en
Publication of WO2004012662A3 publication Critical patent/WO2004012662A3/en
Priority to AU2009213085A priority patent/AU2009213085A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Provided are methods of treating cancer, and/or the side effects of cancer therapy, involving the administration of glutamine, optionally in combination with a carbohydrate carrier that enhances the absorption of glutamine.
PCT/US2003/023987 2002-08-01 2003-07-31 Improved treatment of cancer with glutamine WO2004012662A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
NZ538405A NZ538405A (en) 2002-08-01 2003-07-31 Improved treatment of cancer with glutamine and carbohydrate
JP2004526274A JP4664071B2 (en) 2002-08-01 2003-07-31 Improved treatment of cancer with glutamine
ES03767028T ES2405287T3 (en) 2002-08-01 2003-07-31 Improved treatment of glutamine cancer
CA2493764A CA2493764C (en) 2002-08-01 2003-07-31 Improved treatment of cancer with glutamine
EP03767028.8A EP1572093B1 (en) 2002-08-01 2003-07-31 Prevention of cancer with glutamine
MXPA05001267A MXPA05001267A (en) 2002-08-01 2003-07-31 Improved treatment of cancer with glutamine.
AU2003257963A AU2003257963B2 (en) 2002-08-01 2003-07-31 Improved treatment of cancer with glutamine
IL166475A IL166475A (en) 2002-08-01 2005-01-25 Use of glutamine or carbohydrate in the manufacture of a composition for protecting non-mucosal tissue against damage from radiation therapy
AU2009213085A AU2009213085A1 (en) 2002-08-01 2009-09-11 Improved treatment of cancer with glutamine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40044602P 2002-08-01 2002-08-01
US60/400,446 2002-08-01

Publications (2)

Publication Number Publication Date
WO2004012662A2 WO2004012662A2 (en) 2004-02-12
WO2004012662A3 true WO2004012662A3 (en) 2005-09-29

Family

ID=31495824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/023987 WO2004012662A2 (en) 2002-08-01 2003-07-31 Improved treatment of cancer with glutamine

Country Status (12)

Country Link
US (2) US7709529B2 (en)
EP (1) EP1572093B1 (en)
JP (2) JP4664071B2 (en)
CN (1) CN1802152A (en)
AU (2) AU2003257963B2 (en)
CA (1) CA2493764C (en)
ES (1) ES2405287T3 (en)
IL (1) IL166475A (en)
MX (1) MXPA05001267A (en)
NZ (1) NZ538405A (en)
WO (1) WO2004012662A2 (en)
ZA (1) ZA200500614B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438075A (en) 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
CA2374003C (en) * 1999-05-17 2008-02-12 Aesgen, Inc. Improved cellular uptake of bioactive agents
EP1572093B1 (en) * 2002-08-01 2013-04-17 Eisai Inc. Prevention of cancer with glutamine
TWI351284B (en) 2004-04-09 2011-11-01 Chugai Pharmaceutical Co Ltd Novel water-soluble prodrugs
US20060058390A1 (en) * 2004-09-14 2006-03-16 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
PL372183A1 (en) 2005-01-11 2006-07-24 Sgp & Sons Ab Anticancer drug as well as application of the anticancer drug
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CN101073564B (en) * 2006-05-19 2010-10-13 山东轩竹医药科技有限公司 Medicinal composition containing L-glutamine
WO2008123298A1 (en) * 2007-03-26 2008-10-16 Hirofumi Matsui Infusion preparation for cancer patient
EP2205674B1 (en) * 2007-10-22 2019-04-17 Trinseo Europe GmbH Polymeric compositions and processes for molding articles
EP2687209A1 (en) * 2008-09-19 2014-01-22 Nestec S.A. Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor
CN102164595A (en) 2008-09-19 2011-08-24 雀巢产品技术援助有限公司 Nutritional support of the immune system during anti-cancer treatment
JO3634B1 (en) 2009-11-17 2020-08-27 Novartis Ag Method of treating proliferative disorders and other ‎pathological conditions mediated by bcr-abl, c-kit, ddr1, ‎ddr2 or pdgf-r kinase activity
US8445466B2 (en) * 2010-04-08 2013-05-21 John H. Owoc Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof
GB201108343D0 (en) * 2011-05-18 2011-06-29 Hibernation Honey Ltd Honey composition
WO2015022927A1 (en) * 2013-08-12 2015-02-19 ゼリア新薬工業株式会社 Amp-activated protein kinase activator
US9849144B2 (en) 2013-09-16 2017-12-26 Healios Oncology Nutrition, LLC Glutamine and trehalose compositions
RU2557136C1 (en) * 2014-02-07 2015-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия" Министерства Здравоохранения Российской Федерации (ГБОУ ВПО НижГМА Минздрава России) Method of treating chemical burn of oesophagus and stomach experimentally
CN106789794B (en) * 2016-11-30 2019-05-28 厦门大学 A kind of bionical communication means modulated using dolphin signal of communication frequency modulation
WO2018102715A1 (en) * 2016-12-02 2018-06-07 Indiana University Research And Technology Corporation Compositions and methods for treating and/or reducing corneal dystrophy
US20230277490A1 (en) * 2020-07-31 2023-09-07 Cedars-Sinai Medical Center Glutamine as an anticancer therapy in solid tumors
EP4190173A1 (en) 2020-09-23 2023-06-07 Aminovita S.L. Metabolic cancer therapy
CN115606810A (en) * 2022-10-12 2023-01-17 美雅健康江苏有限公司 Food with efficacy enhancing and toxicity reducing effects of radiotherapy and chemotherapy of tumor, preparation process and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248697A (en) * 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
US20030099722A1 (en) * 2001-10-09 2003-05-29 Baxter Jeffrey H. Methods and compositions for providing glutamine

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2283817A (en) * 1941-05-24 1942-05-19 William R Warner & Company Inc Detoxicant
US2868693A (en) * 1956-07-16 1959-01-13 Shive William Peptic ulcer-treating compositions containing glutamine
US3058942A (en) * 1958-07-07 1962-10-16 Standard Oil Company Of Chicag Polyvinyl chloride homogenized with triisobutyl trimesate and method of preparation
NL272604A (en) * 1960-12-28
US3957964A (en) * 1974-01-30 1976-05-18 Colgate-Palmolive Company Dentifrice containing encapsulated flavoring
US4071614A (en) * 1975-06-03 1978-01-31 Colgate Palmolive Company Dentifrice containing encapsulated flavoring
US4348378A (en) * 1979-08-09 1982-09-07 Kosti Carl M Plaque disclosing dentifrice compositions with semi-solid microcapsules of dye
JPS6030650B2 (en) 1979-10-26 1985-07-17 日本油脂株式会社 Suppository base composition
US4352825A (en) * 1981-02-23 1982-10-05 Nabisco Brands, Inc. Coextruded chewing gum containing a soft core portion
US4352823A (en) * 1981-04-13 1982-10-05 Nabisco Brands, Inc. Coextruded chewing gum containing a soft non-SBR gum core portion
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US4439194A (en) 1981-09-08 1984-03-27 Merck & Co., Inc. Water and drug delivery system for suppository use
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
US4647459A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Confectionery compositions containing magnesium trisilicate adsorbates
LU84979A1 (en) 1983-08-30 1985-04-24 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US5397803A (en) * 1985-09-12 1995-03-14 Brigham And Women's Hospital Use of glutamine to reduce rate of pathogenic microorganism infection
US5763485A (en) * 1985-09-12 1998-06-09 Brigham And Women's Hospital Method of treating catabolic, gut-associated pathological processes and impaired host defenses
US5684045A (en) * 1985-09-12 1997-11-04 Brigham And Women's Hospital Method of treating pancreatic atrophy
US4857555A (en) * 1985-09-12 1989-08-15 Brigham & Women's Hospital Method of treating catabolic dysfunction
US5039704A (en) * 1985-09-12 1991-08-13 Brigham And Women's Hospital Method of treating catabolic dysfunction
CA1285491C (en) 1985-09-12 1991-07-02 Robert J. Smith Method of treating catabolic dysfunction
DE3601398A1 (en) 1986-01-18 1987-07-23 Fresenius Ag USE OF OLIGOPEPTIDES FOR THE TREATMENT OF CEREBRAL DISORDERS
US4983595A (en) * 1986-05-22 1991-01-08 Syntex (U.S.A.) Inc. Aqueous steroid formulations for nasal administration
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US6099457A (en) * 1990-08-13 2000-08-08 Endotech, Inc. Endocurietherapy
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5160331A (en) * 1991-07-12 1992-11-03 Progeny Products, Inc. Absorbent insert
US5658895A (en) * 1991-10-07 1997-08-19 Otsuka Pharmaceutical Factory, Inc. Anticancer enteral feeding composition
JPH06192108A (en) 1992-12-25 1994-07-12 Kanebo Ltd Calcium gluconate oral solution
US5366723A (en) * 1993-03-05 1994-11-22 Istvan Tulok Method of alleviating toxicity originating from treatment with anticancer platinum compounds
IL108366A (en) 1993-03-11 1999-11-30 Taro Vit Ind Ltd Pharmaceutical compositions in semisolid form and a squeezable container for administration thereof
US5438075A (en) * 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
JPH0782225A (en) * 1993-09-14 1995-03-28 Fuji Photo Film Co Ltd Amino acid derivative and its use
US5438042B1 (en) * 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
GB9418530D0 (en) 1994-09-14 1994-11-02 Glaxo Group Ltd Medicaments
US5726146A (en) * 1994-12-06 1998-03-10 Natural Supplement Association, Incorporated Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass
US5569466A (en) 1995-05-17 1996-10-29 R. P. Scherer Corporation Fill compositions for soft elastic gel capsules
JPH11292787A (en) 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd Transucosal preparation containing physiologically active peptide
DE19533330A1 (en) * 1995-09-11 1997-03-13 Beiersdorf Ag Anti-skin cancer topical preparations
WO1997014310A1 (en) 1995-10-13 1997-04-24 Novo Nordisk A/S Fungicidal carbohydrate preparations
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5714005A (en) * 1995-12-20 1998-02-03 Motorola Inc. ST-cut and AT-cut oriented seed bodies for quartz crystal synthesis and method for making the same
JPH09187233A (en) 1996-01-12 1997-07-22 Ota Seiyaku Kk Jelly composition
EP0873749B1 (en) 1996-01-12 2006-03-29 Ohta Pharmaceutical Co., Ltd. Jellied medicinal composition for oral administration
US5716959A (en) * 1996-02-13 1998-02-10 T. Ronald Theodore Method of treating disease with piperazine zwitterion compounds
US5891467A (en) * 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
WO1998043643A1 (en) 1997-04-01 1998-10-08 Toa Medicine Co., Ltd. Aqueous acyclovir solution preparations
US5849335A (en) * 1997-06-02 1998-12-15 Nestec S.A. Composition and method for providing glutamine
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
US6159492A (en) * 1999-03-04 2000-12-12 Manzone; Cheryl Drug storage and delivery system containing a medicated lollipop
CA2374003C (en) 1999-05-17 2008-02-12 Aesgen, Inc. Improved cellular uptake of bioactive agents
WO2001078783A2 (en) * 2000-04-17 2001-10-25 Hauser, Inc. Compositions comprising natural agents for treatment of cancer
US6391332B1 (en) * 2000-04-20 2002-05-21 Baxter International, Inc. Therapeutic micronutrient composition for severe trauma, burns and critical illness
US6479068B1 (en) * 2000-06-30 2002-11-12 Baxter International Inc. Therapeutic nutrient regimen for alleviating mucositis, stomatitis and cachexia in oncology patients
EP1468036B1 (en) * 2002-01-14 2008-10-08 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
EP1572093B1 (en) * 2002-08-01 2013-04-17 Eisai Inc. Prevention of cancer with glutamine
US20040265359A1 (en) * 2003-04-17 2004-12-30 Sacks Gordon S. Oral delivery formulations of L-glutamine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248697A (en) * 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
US20030099722A1 (en) * 2001-10-09 2003-05-29 Baxter Jeffrey H. Methods and compositions for providing glutamine

Also Published As

Publication number Publication date
CA2493764A1 (en) 2004-02-12
EP1572093A2 (en) 2005-09-14
CN1802152A (en) 2006-07-12
ZA200500614B (en) 2007-12-27
IL166475A (en) 2014-07-31
MXPA05001267A (en) 2005-10-18
ES2405287T3 (en) 2013-05-30
US7709529B2 (en) 2010-05-04
IL166475A0 (en) 2006-01-15
US20050090451A1 (en) 2005-04-28
US20100152130A1 (en) 2010-06-17
JP2009256357A (en) 2009-11-05
AU2003257963B2 (en) 2009-08-13
EP1572093B1 (en) 2013-04-17
NZ538405A (en) 2007-12-21
WO2004012662A2 (en) 2004-02-12
EP1572093A4 (en) 2008-04-09
JP2006509723A (en) 2006-03-23
JP4664071B2 (en) 2011-04-06
AU2009213085A1 (en) 2009-10-08
AU2003257963A1 (en) 2004-02-23
JP5496549B2 (en) 2014-05-21
CA2493764C (en) 2011-05-24

Similar Documents

Publication Publication Date Title
WO2004012662A3 (en) Improved treatment of cancer with glutamine
WO2004103301A3 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
MX368013B (en) Cancer treatment.
AU2003254038A1 (en) Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2006015263A3 (en) Lonidamine analogs
WO2005070052A3 (en) Use of photodynamic therapy to enhance treatment with immuno-modulating agents
WO2004058187A3 (en) Photo-reactive polymers and devices for use in hair treatments
HK1080447B (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
WO2005000211A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
UA87877C2 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
WO2005076888A3 (en) Anti-cancer therapies
AU2158601A (en) Antiviral agent for use in treatment of cancer
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2002056835A3 (en) Anticancer treatment using triptolide prodrugs
WO2004080421A3 (en) Improved antitumoral treatments
HUP0400153A2 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
WO2001034131A3 (en) Combination chemotherapy
WO2006071955A3 (en) Glufosfamide combination therapy
WO2003047697A3 (en) Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
WO2006069217A3 (en) Small molecule cyclin d1 ablative agents
WO2005034868A8 (en) Methods for treating igf1r-inhibitor induced hyperglycemia
WO2004045497A3 (en) Cd26-based therapies for cancers and immune disease
WO2005094282A3 (en) Combination therapy comprising cloretazinetm

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005/00614

Country of ref document: ZA

Ref document number: 200500614

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 166475

Country of ref document: IL

Ref document number: 2003257963

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2493764

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001267

Country of ref document: MX

Ref document number: 2004526274

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003767028

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 538405

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 291/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003823601X

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003767028

Country of ref document: EP